Finance

Lists
Q3 2026 earnings • in 3 days
See details
GERN:NASDAQ
Geron Corp
$0.89
-5.47%
(-0.052) 1D
$0.89
-0.48% (-0.0043)
After hours
Closed: Oct 30, 3:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GERN...
Open
$0.93
High
$0.94
Low
$0.86
Mkt. cap
572.33M
Avg. vol.
11.47M
Volume
18.81M
52-wk high
$2.01
52-wk low
$0.84
EPS
-$0.10
Beta
0.61
Shares outstanding
642.47M
No. of employees
258
Open
$0.93
High
$0.94
Low
$0.86
Mkt. cap
572.33M
Avg. vol.
11.47M
Volume
18.81M
52-wk high
$2.01
52-wk low
$0.84
EPS
-$0.10
Beta
0.61
Shares outstanding
642.47M
No. of employees
258
News stories
From web sources and news partners
Profile
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase. Wikipedia
About Geron Corp
CEOJohn A Scarlett
Employees258
Founded1990
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegeron.com
Analyst ratings
Based on 4 analysts giving stock ratings to GERN in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for GERN in the last 3 months.
Highest
Current $0.89
$5.00 (+459.03%)
Average
$4.00 (+347.23%)
Lowest
$3.00 (+235.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Reiterated
$5.00
+459%
10/29/2026
Tara Bancroft
TD Cowen
Buy
Maintained
$3.00
+235.4%
10/21/2026
Emily Bodnar
H.C. Wainwright
Hold
Maintained
-
-
09/21/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$6.00
+570.8%
08/06/2026
Gil Blum
Needham
Buy
Maintained
$4.00
+347.2%
08/05/2026
Corinne Johnson
Goldman Sachs
Sell
Reiterated
$1.00
+11.8%
02/25/2026
Next call in 3 days
Wed, Nov 4, 3:00 PM
Fiscal period
Q3 2026
- / -$0.01
Revenue / Est. (USD)
- / 60.36M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
47.23M
48.02M
51.84M
57.48M
Cost of goods sold
22.11M
14.86M
16.65M
31.27M
Cost of revenue
22.11M
14.86M
16.65M
31.27M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39.00M
41.67M
35.42M
38.86M
Operating expense
39.00M
41.67M
35.42M
38.86M
Total operating expenses
61.11M
56.52M
52.07M
70.13M
Operating income
-13.89M
-8.51M
-236.00K
-12.65M
Other non operating income
-161.00K
-70.00K
-74.00K
-9.00K
EBT including unusual items
-18.43M
-28.86M
-3.64M
-16.68M
EBT excluding unusual items
-18.43M
-11.83M
-4.04M
-16.84M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18.43M
-28.86M
-3.64M
-16.68M
Net profit margin
-39.02%
-60.11%
-7.03%
-29.02%
Earnings per share
-0.03
-0.02
-0.00
-0.02
Interest and investment income
4.26M
4.04M
3.42M
2.97M
Interest expense
-8.64M
-7.30M
-7.15M
-7.15M
Net interest expenses
-4.38M
-3.25M
-3.73M
-4.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.76M
-8.42M
-102.00K
-12.52M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps